Skip to main content
. 2018 Nov 5;38(1):e99506. doi: 10.15252/embj.201899506

Figure 7. VGLL4 expression predicts cancer patient outcome and correlates with IRF2BP2 levels in non‐small‐cell lung cancer.

Figure 7

  1. Representative immunohistochemical staining for VGLL4 and IRF2BP2 in human non‐small‐cell lung cancer tissues. IHC score is indicated. Scale bar: 50 μm.
  2. Staining of VGLL4 and IRF2BP2 on human non‐small‐cell lung cancer tissue arrays containing 71 samples was quantified as described in the Materials and Methods section. Correlation of VGLL4 and IRF2BP2 expressions was significant (Pearson correlation test; R = 0.6341, P < 0.001).
  3. Correlation analysis of VGLL4 and PD‐L1 expression on human non‐small‐cell lung cancer tissue arrays containing 71 samples.
  4. Kaplan–Meier survival analysis of patients with high (n = 74) or low (n = 130) VGLL4 mRNA levels from GSE31210, a lung cancer data set. Survival curves are calculated according to the Kaplan–Meier method.
  5. Model for the regulation of PD‐L1 expression by VGLL4 and YAP. VGLL4 regulates PD‐L1 expression through controlling IRF2BP2 protein stability. YAP represses IFNγ‐inducible PD‐L1 expression partially through miR‐130a‐mediated inhibition of VGLL4 and IRF1 expression.